Shepherd Kaplan Krochuck and Molex Ventures have helped the epinephrine pen developer raise $12.1m of a funding round expected to close at $39m.
Molex Ventures, a subsidiary of manufacturing, chemicals and energy conglomerate Koch Industries, has invested in US-based pharmaceutical device developer Windgap Medical, in a round sized at $12.1m according to a regulatory filing.
The company said the round is being led by financial services provider Shepherd Kaplan Krochuck, and it has targeted a $39m close according to the filing. Molex Ventures invests on behalf of Koch medical device subsidiary Molex.
Founded in 2011, Windgap is developing an epinephrine pen called AndiPen…
